Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001104659-23-072222
Filing Date
2023-06-16
Accepted
2023-06-16 16:05:38
Documents
1
Period of Report
2023-06-14

Document Format Files

Seq Description Document Type Size
1 OWNERSHIP DOCUMENT tm2318991-1_4seq1.html 4  
1 OWNERSHIP DOCUMENT tm2318991-1_4seq1.xml 4 4589
  Complete submission text file 0001104659-23-072222.txt   6285
Mailing Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016
Business Address 20 COMMERCE DRIVE, SUITE 135 CRANFORD NJ 07016 732-980-4500
ENZON PHARMACEUTICALS, INC. (Issuer) CIK: 0000727510 (see all company filings)

EIN.: 222372868 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O NEW YORK REIT, INC. 405 PARK AVENUE NEW YORK NY 10022
Business Address
READ RANDOLPH C (Reporting) CIK: 0001074613 (see all company filings)

Type: 4 | Act: 34 | File No.: 000-12957 | Film No.: 231020984